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Letters to the Editor
Is There an Optimal
Hematocrit Value for Cardiac Patients?
The significance of anemia in congestive heart failure (CHF) has
only recently received attention, as evidenced by two state-of-the-
art papers published over the last several months (1,2). Anemia is
more common in CHF than could be accounted for by age or the
degree of renal dysfunction (2). Moderate to severe anemia can
contribute to the development or worsening of CHF. Conversely,
CHF can lead to moderate anemia (2). Recent reports have largely
resolved the question: Is anemia a cause or a consequence of CHF?
(3). Erythropoietin, which has a long history in the management of
anemia complicating chronic renal failure, is being used for
treatment of anemia in CHF (4–6).
Besides the potential risks of worsening hypertension and
increased thrombosis as pointed out by Felker et al. (1), anemia
correction in CHF may have other adverse effects. High hemato-
crit has been reported to be associated with a higher rate of Q-wave
myocardial infarction (MI) after coronary artery bypass grafting
(7). That a high hematocrit value was associated with an increased
risk for MI has actually been known for a long time (8). As a
matter of fact, George Burch (9–14), who wrote extensively on the
subject since the early 1960s, advocated bloodletting in patients
with coronary artery disease with a high hematocrit value (13,14).
It might be appropriate to quote what Burch wrote in 1979 (14):
“It is well known that a high hematocrit is associated with
high viscosity and that a highly viscous fluid requires more
work of the pump to circulate it than does a less viscous
liquid. Furthermore, the flow of highly viscous fluid is
reduced, even with all else being equal. Nevertheless, phy-
sicians fail to bleed patients with active coronary disease and
myocardial ischemia, whose hematocrit is high and whose
blood viscosity is increased. It has been shown that blood-
letting in patients with ischemic heart disease definitely
improved the clinical state of these patients when their
hematocrit was reduced to average normal levels.”
Therefore, as Felker et al. (1) cautioned, one must balance the risk
of correcting the anemia in CHF against the risks of such
treatment. What the optimal hematocrit value should be for
patients with coronary artery disease or CHF has to await the
results of controlled studies on a large number of patients.
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Further Aspects of Anemia,
Heart Failure, and Erythropoietin
A routine laboratory hemoglobin measurement reflects “hemoglo-
bin concentration.” This approximates the total-body circulating
hemoglobin (TBH) to plasma volume (PV) ratio, but provides no
absolute quantitative information about either TBH or PV. Ane-
mia arises when the TBH:PV ratio falls. This occurs with either
decreased TBH or increased PV. This distinction is important: in a
recent study, 46% of anemic patients with heart failure had a normal
total red cell volume, with anemia attributable to excess PV (1).
In their review, Felker et al. (2) raise several issues concerning
anemia and heart failure that warrant further consideration. They
adopt the term “true anemia” to describe a decrease in TBH (2).
This begs the question: is a reduced hemoglobin concentration any
truer if it arises from decreased TBH rather than increased PV?
Undoubtedly not, and the term “true anemia” should probably be
avoided as it is imprecise. Felker et al. also indicate that “anemia
results in decreased oxygen-carrying capacity” (2). Again, this
statement is imprecise. It is a decrease in TBH that results in
decreased oxygen-carrying capacity.
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Felker et al. (2) do not consider that anemia can be a normal
adaptation to increased cardiovascular demand. Both athletic
training (3–5) and pregnancy (6) cause a simultaneous increase in
TBH and PV, with the increase in PV being relatively greater than
the increase in TBH (3–6). This results in an increased total blood
volume, reduced blood viscosity, and anemia—an adaptation that
potentially enhances total-blood oxygen-carrying capacity, while
concurrently decreasing blood viscosity (6,7).
Although not widely studied in heart failure, the importance of
blood viscosity was given little consideration by Felker et al. (2). At
a fixed hematocrit, cardiac output is enhanced as blood viscosity
decreases (8). Blood viscosity is also inversely related to physical
performance in athletes (7). Anemia in heart failure is undoubtedly
the end result of multiple pathological pathways (2). However, a
possible physiologic benefit (reduced blood viscosity) should not be
discounted, and the broader consequences of increased blood
viscosity from erythropoietin (EPO) therapy require careful con-
sideration.
Felker et al. (2) provided little information on the impressive
direct cardioprotective actions of EPO (9). Furthermore, research
published after the Felker et al. (2) study appeared suggests that,
from an evolutionary perspective, cardioprotection was one of
EPO’s original functions (10), and derivatives of EPO, devoid of
an erythropoietic action, retain tissue-protective effects (11).
Despite positive results in small studies (2), the large, random-
ized Normal Hematocrit Treatment trial of EPO in anemic
dialysis patients with cardiac disease was largely negative (12). This
should serve as a cautionary note, and the notion that the
appropriate attitude toward EPO therapy in heart failure is “a
mixture of optimism and caution” (2) needs expanding. It is
difficult to reconcile EPO therapy in anemic patients with normal
TBH but with expanded PV. Given the potentially adverse
consequences of EPO (increased blood viscosity and other detri-
mental sequelae [2]) it would seem prudent to initially restrict
human trials of EPO in heart failure to patients with decreased
TBH.
Finally, EPO or its derivatives are a promising potential
adjunctive therapy for heart failure, but to realize this potential a
meticulous and rigorous approach is imperative.
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REPLY
We appreciate the interest of Drs. Kovacic and Cheng in our
report (1) on the relationship between heart failure and anemia.
We agree on the need for careful assessment of risks and benefits
when evaluating any new therapeutic approach in heart failure. Dr.
Kovacic correctly points out that anemia is technically the result of
a decrease in red blood cell mass rather than a decreased hemo-
globin concentration (2). Because accurate quantification of red
cell mass requires labeled red blood cell scanning, hemoglobin
concentration is frequently employed as a readily available surro-
gate in clinical practice. We concede that in states of plasma
expansion (such as heart failure, renal failure, or pregnancy),
hemoglobin concentration may not accurately reflect red blood cell
mass. Our use of the terms “true anemia” and “hemodilution”
reflected the terminology used in the study by Androne et al. (3),
and we believe this nomenclature accurately describes the two
mechanisms for decreased hemoglobin concentration described
above.
Dr. Kovacic’s assertion that decreased hemoglobin concentra-
tion from plasma expansion in patients with heart failure may
represent a “normal adaptation to increased cardiovascular de-
mand” that has a “possible physiologic benefit (reduced blood
viscosity)” is not supported by the data from Androne et al., which
demonstrated a worse prognosis in patients with “hemodilution”
compared to those with “true anemia” (3).
Both Drs. Cheng and Kovacic cite the potentially important
role of blood viscosity in understanding the cardiovascular effects of
anemia. Dr. Cheng appropriately points out that very elevated
hematocrit levels (generally 50%) are associated with increased
blood viscosity, which could potentially increase the risk for
ischemic cardiac events. However, the studies by Burch and
DePasquale cited by Dr. Cheng evaluated “bloodletting” in pa-
tients with hematocrit in the upper range of normal or above
normal (almost always 50%) (4–6). In contrast, preliminary
therapeutic studies using erythropoietin analogs in heart failure
have generally targeted a modest rise in hemoglobin with a goal
hemoglobin corresponding to a hematocrit below 40% (7,8).
Notably, this is still well below the target hematocrit from
phlebotomy suggested by Burch of 45% for men and 42% for
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